Amphastar Pharmaceuticals, Inc. (AMPH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 263.20M USD | Liabilities, Current |
| Cash and equivalents | 223.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 144.86M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 179.91M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $263.20M | $223.61M | (m) | $144.86M | $179.91M | (m) |
| 2026-03-31 | (m) | $164.48M | $170.94M | (m) | $147.85M | $170.19M | (m) |
| 2025-12-31 | (m) | $158.16M | $170.18M | (m) | $143.56M | $176.89M | (m) |
| 2025-09-30 | (m) | $205.23M | $216.26M | (m) | $146.81M | $185.93M | (m) |
| 2025-06-30 | (m) | $176.41M | $187.69M | (m) | $132.98M | $191.73M | (m) |
| 2025-03-31 | (m) | $199.05M | $182.78M | (m) | $144.64M | $185.48M | (m) |
| 2024-12-31 | (m) | $173.76M | $151.61M | (m) | $136.29M | $153.74M | (m) |
| 2024-09-30 | (m) | $159.01M | $192.12M | (m) | $139.63M | $130.32M | (m) |
| 2024-06-30 | (m) | $136.97M | $189.62M | (m) | $131.41M | $122.41M | (m) |
| 2024-03-31 | (m) | $255.17M | $201.15M | (m) | $138.11M | $115.49M | (m) |
| 2023-12-31 | (m) | $225.41M | $144.30M | (m) | $114.94M | $105.83M | (m) |
| 2023-09-30 | (m) | $257.96M | $266.78M | (m) | $118.99M | $109.98M | (m) |
| 2023-06-30 | (m) | $251.28M | $148.59M | (m) | $104.72M | $104.62M | (m) |
| 2023-03-31 | (m) | $105.64M | $176.62M | (m) | $100.64M | $103.65M | (m) |
| 2022-12-31 | (m) | $94.86M | $156.10M | (m) | $88.80M | $103.58M | (m) |
| 2022-09-30 | (m) | $102.19M | $157.24M | (m) | $77.10M | $103.25M | (m) |
| 2022-06-30 | (m) | $103.63M | $166.16M | (m) | $80.81M | $98.73M | (m) |
| 2022-03-31 | (m) | $114.36M | $172.63M | (m) | $73.17M | $95.15M | (m) |
| 2021-12-31 | (m) | $103.81M | $126.35M | (m) | $78.80M | $92.81M | (m) |
| 2021-09-30 | (m) | $97.99M | $106.61M | (m) | $78.09M | $100.24M | (m) |
| 2021-06-30 | (m) | $124.55M | $105.43M | (m) | $67.89M | $97.93M | (m) |
| 2021-03-31 | (m) | $127.10M | $101.60M | (m) | $77.94M | $97.11M | (m) |
| 2020-12-31 | (m) | $112.20M | $92.64M | (m) | $66.00M | $96.83M | (m) |
| 2020-09-30 | (m) | $96.72M | $87.91M | (m) | $52.38M | $108.87M | (m) |
| 2020-06-30 | (m) | $93.29M | $87.39M | (m) | $49.86M | $104.73M | (m) |
| 2020-03-31 | (m) | $83.37M | $54.84M | (m) | $57.78M | $107.90M | (m) |
| 2019-12-31 | (m) | $90.01M | $73.69M | (m) | $45.38M | $110.50M | (m) |
| 2019-09-30 | (m) | $86.60M | $85.61M | (m) | $45.26M | $109.85M | (m) |
| 2019-06-30 | (m) | $101.00M | $120.37M | (m) | $48.82M | $99.23M | (m) |
| 2019-03-31 | (m) | $111.96M | $79.10M | (m) | $54.93M | $78.58M | (m) |
| 2018-12-31 | (m) | $106.83M | $86.34M | (m) | $52.16M | $69.32M | (m) |
| 2018-09-30 | (m) | $96.62M | $68.73M | (m) | $43.82M | $65.41M | (m) |
| 2018-06-30 | (m) | $87.59M | $48.07M | (m) | $41.28M | $61.68M | (m) |
| 2018-03-31 | (m) | $72.54M | $54.55M | (m) | $31.88M | $62.78M | (m) |
| 2017-12-31 | (m) | $67.19M | $65.59M | (m) | $36.00M | $63.61M | (m) |
| 2017-09-30 | (m) | $57.40M | $66.92M | (m) | $24.15M | $69.64M | (m) |
| 2017-06-30 | (m) | $63.70M | $82.54M | (m) | $24.12M | $74.46M | (m) |
| 2017-03-31 | (m) | $72.86M | $76.77M | (m) | $25.89M | $78.14M | (m) |
| 2016-12-31 | (m) | $60.62M | $72.35M | (m) | $26.78M | $79.75M | (m) |
| 2016-09-30 | (m) | $60.84M | $66.60M | (m) | $26.55M | $90.65M | (m) |
| 2016-06-30 | (m) | $65.67M | $66.66M | (m) | $23.13M | $88.33M | (m) |
| 2016-03-31 | (m) | $64.92M | $63.33M | (m) | $23.08M | $82.24M | (m) |
| 2015-12-31 | (m) | $59.95M | $66.07M | (m) | $33.23M | $70.67M | (m) |
| 2015-09-30 | (m) | $70.65M | $70.68M | (m) | $25.00M | $72.42M | (m) |
| 2015-06-30 | (m) | $69.40M | $74.46M | (m) | $19.83M | $80.17M | (m) |
| 2015-03-31 | (m) | $72.09M | $68.59M | (m) | $21.65M | $84.89M | (m) |
| 2014-12-31 | (m) | $62.59M | $67.83M | (m) | $22.85M | $82.33M | (m) |
| 2014-09-30 | (m) | $63.08M | $72.88M | (m) | $26.60M | $88.05M | (m) |
| 2014-06-30 | (m) | $56.28M | $64.08M | (m) | $18.60M | $106.02M | (m) |
| 2014-03-31 | (m) | (m) | $52.13M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $65.40M | $53.59M | (m) | $24.59M | $69.92M | (m) |
| 2013-09-30 | (m) | (m) | $51.94M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $55.95M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $50.21M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $53.74M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |